Current and Emerging Targets in Immunotherapy for Osteosarcoma

被引:84
|
作者
Miwa, Shinji [1 ]
Shirai, Toshiharu [1 ,2 ]
Yamamoto, Norio [1 ]
Hayashi, Katsuhiro [1 ]
Takeuchi, Akihiko [1 ]
Igarashi, Kentaro [1 ]
Tsuchiya, Hiroyuki [1 ]
机构
[1] Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 9208640, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kyoto 6028566, Japan
关键词
SOFT-TISSUE SARCOMA; LIPOSOMAL MURAMYL TRIPEPTIDE; AUTOLOGOUS TUMOR LYSATE; HIGH-GRADE OSTEOSARCOMA; PULSED DENDRITIC CELLS; DEATH LIGAND 1; T-CELLS; INTRAVENOUS-INJECTION; MONOCYTE ACTIVATION; REFRACTORY BONE;
D O I
10.1155/2019/7035045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Current and emerging pharmacological targets for medical expulsive therapy
    Lim, Iris
    Sellers, Donna J.
    Chess-Williams, Russ
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 : 16 - 22
  • [42] Current and emerging therapeutic targets for Parkinson's disease
    Pingale, Tanvi
    Gupta, Girdhari Lal
    METABOLIC BRAIN DISEASE, 2021, 36 (01) : 13 - 27
  • [43] Advances on immunotherapy for osteosarcoma
    Yu, Shengnan
    Yao, Xudong
    MOLECULAR CANCER, 2024, 23 (01)
  • [44] ADOPTIVE IMMUNOTHERAPY IN OSTEOSARCOMA
    ENNEKING, WF
    GAINOR, B
    NEFF, JR
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1974, A 56 (07): : 1536 - 1536
  • [45] IMMUNOTHERAPY OF MURINE OSTEOSARCOMA
    MILLER, CW
    MCLAUGHLIN, RE
    CHAPPEL, EJ
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1975, A 57 (04): : 584 - 584
  • [46] Is There a Role for Immunotherapy in Osteosarcoma?
    Loeb, David M.
    PEDIATRIC AND ADOLESCENT OSTEOSARCOMA, 2009, 152 : 447 - 457
  • [47] Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
    Kimberly M. Komatsubara
    Richard D. Carvajal
    Current Oncology Reports, 2017, 19
  • [48] Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence
    Vaidya, Poorva
    Cohen, Ezra E. W.
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1232 - 1239
  • [49] Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
    Chiec, Lauren
    Bruno, Debora S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [50] Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
    Chakravarty, Dimple
    Huang, Li
    Kahn, Matthew
    Tewari, Ashutosh K.
    UROLOGIC CLINICS OF NORTH AMERICA, 2020, 47 (04) : 487 - 510